NexgenRx (NXG) Stock Overview
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
NXG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
NexgenRx Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.38 |
| 52 Week High | CA$0.42 |
| 52 Week Low | CA$0.23 |
| Beta | 0.86 |
| 1 Month Change | -2.56% |
| 3 Month Change | 8.57% |
| 1 Year Change | 38.18% |
| 3 Year Change | 52.00% |
| 5 Year Change | 123.53% |
| Change since IPO | 8.57% |
Recent News & Updates
Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 29% But Growth Is Lacking
Jul 01
Pinning Down NexgenRx Inc.'s (CVE:NXG) P/S Is Difficult Right Now
Apr 07Recent updates
Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 29% But Growth Is Lacking
Jul 01Pinning Down NexgenRx Inc.'s (CVE:NXG) P/S Is Difficult Right Now
Apr 07Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking
May 21We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
May 10NexgenRx Inc.'s (CVE:NXG) Price Is Out Of Tune With Revenues
Mar 14Here's Why We Think NexgenRx (CVE:NXG) Might Deserve Your Attention Today
Mar 07Is Now The Time To Put NexgenRx (CVE:NXG) On Your Watchlist?
Oct 18Does NexgenRx (CVE:NXG) Deserve A Spot On Your Watchlist?
Nov 30What NexgenRx Inc.'s (CVE:NXG) 32% Share Price Gain Is Not Telling You
Aug 24Here's Why NexgenRx Inc.'s (CVE:NXG) CEO May Have Their Pay Bumped Up
Jun 03NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 19
How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?
Dec 28Shareholder Returns
| NXG | CA Insurance | CA Market | |
|---|---|---|---|
| 7D | 0% | -0.6% | -0.4% |
| 1Y | 38.2% | 17.6% | 19.9% |
Return vs Industry: NXG exceeded the Canadian Insurance industry which returned 17.6% over the past year.
Return vs Market: NXG exceeded the Canadian Market which returned 19.9% over the past year.
Price Volatility
| NXG volatility | |
|---|---|
| NXG Average Weekly Movement | n/a |
| Insurance Industry Average Movement | 2.6% |
| Market Average Movement | 9.9% |
| 10% most volatile stocks in CA Market | 20.5% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: NXG's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: Insufficient data to determine NXG's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Ron Loucks | www.nexgenrx.com |
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. The company offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. It also provides ancillary services.
NexgenRx Inc. Fundamentals Summary
| NXG fundamental statistics | |
|---|---|
| Market cap | CA$27.02m |
| Earnings (TTM) | CA$804.43k |
| Revenue (TTM) | CA$17.17m |
Is NXG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXG income statement (TTM) | |
|---|---|
| Revenue | CA$17.17m |
| Cost of Revenue | CA$3.44m |
| Gross Profit | CA$13.72m |
| Other Expenses | CA$12.92m |
| Earnings | CA$804.43k |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.011 |
| Gross Margin | 79.94% |
| Net Profit Margin | 4.69% |
| Debt/Equity Ratio | 0% |
How did NXG perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/03 20:56 |
| End of Day Share Price | 2025/10/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NexgenRx Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.